Pharmaceutical
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has urged EU lawmakers to widen a proposed patent-style incentive in the Biotech Act, warning that the current plan is too narrow to materially shift investment decisions. 15 June 2026
Pharmaceutical
PwC expects US commercial healthcare costs to remain high in 2027, with health plans facing pressure from provider billing, hospital reimbursement, pharmacy spending, behavioral health demand and out-of-network arbitration. 12 June 2026
Pharmaceutical
The global branded drug industry has urged G7 leaders to put pharmaceutical innovation at the center of their economic agenda, in a pre-summit statement that also serves as a clear pitch for policies more favorable to the sector. 11 June 2026
Biotechnology
Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, today announced a multi-year collaboration with Swiss pharma giant Novartis to discover and design molecular glue drugs for challenging therapeutic targets across multiple disease areas. 10 June 2026
Pharmaceutical
UK pharma major GSK revealed it has entered an agreement to acquire Nuvalent, a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies. 9 June 2026
Most Read
Features
Biotechnology
German biotech company Vivoryon Therapeutics is rebuilding its story around diabetic kidney disease. 15 June 2026
Pharmaceutical
Russian drugmaker Pharmstandard plans to build a new complex for the production of live vaccines in the Technopolis special economic zone in the Moscow region, which is expected to be one of the largest of such kind in the country, reports The Pharma Letter’s local correspondent. 15 June 2026
Pharmaceutical
India’s pharma industry is still best known for low-cost generic medicines, vaccines, active ingredients and contract manufacturing. That role remains central to global drug supply, but it no longer describes the full direction of the sector. 12 June 2026
Pharmaceutical
An interview with Anna Petryk, Executive Global Medical Director who leads the global medical affairs team in the Rare Bone and Endocrine Disorders therapeutic area at Alexion, AstraZeneca Rare Disease. 11 June 2026
Company Spotlight
A San Diego-based biopharmaceutical company that has built a $2.83 billion commercial franchise around neurological and endocrine disorders, anchored by INGREZZA in tardive dyskinesia and the first new CAH treatment in roughly seven decades.
Recent news
Biotechnology
New Jersey, USA-based biotech Reunion Neuroscience has appointed Dr Sahil Kirpekar as its new president, chief executive (CEO) and a member of the board of Ddirectors, effective immediately. 16 June 2026
Pharmaceutical
Russia may revise the patent protection terms for drugs with aim to reduce their length from the current 25 years to 15-20 years or even lower. 16 June 2026
Biotechnology
German biotech company Vivoryon Therapeutics is rebuilding its story around diabetic kidney disease. 15 June 2026
Pharmaceutical
Barcelona, Spain-based Grifols today announced the US launch of its new fibrinogen concentrate. 15 June 2026
Biotechnology
Elicio Therapeutics saw its shares plummet nearly 74% to $3.92 in early trading today, after it reported results from its randomized Phase II AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) following completion of standard locoregional therapy. 15 June 2026
Refine search
In Brief
Biotechnology
8 June 2026 US biotech Incyte Pharma is nearing a deal for up to $2 billion to buy privately held blood disorder drug developer Star Therapeutics amid a wave of acquisitions by midsized drugmakers looking to supplement their pipelines, according to a Financial Times report.
Pharmaceutical
26 May 2026 Radiopharmaceutical-focused company Lantheus Holdings is weighing a potential sale after getting a takeover offer from private-equity backed Curium Pharma that values it at about $7 billion, Bloomberg News reported on Friday.
Conferences
20 June 2026 24 June 2026 Kraków, Poland, ICE Kraków Congress Centre
22 June 2026 25 June 2026 California, USA, San Diego Convention Center
22 June 2026 23 June 2026 Massachusetts, USA, The Westin Copley Place
4 July 2026 8 July 2026 Maastricht, The Netherlands, Maastricht Exhibition & Conference Centre
9 July 2026 Cambridge, UK
11 July 2026 15 July 2026 Paris, France, Paris Expo Porte de Versailles
More Events
Insights
Pharmaceutical
India’s pharma industry is still best known for low-cost generic medicines, vaccines, active ingredients and contract manufacturing. That role remains central to global drug supply, but it no longer describes the full direction of the sector. 12 June 2026
Pharmaceutical
An interview with Anna Petryk, Executive Global Medical Director who leads the global medical affairs team in the Rare Bone and Endocrine Disorders therapeutic area at Alexion, AstraZeneca Rare Disease. 11 June 2026
Pharmaceutical
Outsourced manufacturing has become part of the basic infrastructure of the pharma industry. Large drugmakers use it for flexibility, specialist capacity and regional supply. Smaller biotechs use it because most cannot build plants of their own. 11 June 2026
Biotechnology
Biotech companies are still being formed around university science, venture funding and experienced management teams. But the route from scientific idea to new company is changing, and the shift is now visible across the USA, Europe, China and other major innovation hubs. 10 June 2026
Biotechnology
Dr Anna Sureda writes on barriers to access. 9 June 2026
Pharmaceutical
Skin disease is one of the most common health challenges in the world. More than a third of the global population lives with a dermatological condition, ranging from the chronic and inflammatory to the infectious and rare. And yet dermatology remains a field where significant gaps persist: in access, in diagnosis, in conversations at doctor’s offices, and critically, in how well the solutions available reflect the needs of those living with the conditions. 8 June 2026
Generics
Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian pharmaceutical company Amedart announced its plans launch a domestic analogue of Trikafta (elexacaftor/tezacaftor/ivacaftor), a drug from the American company Vertex Pharmaceuticals for the treatment of cystic fibrosis, reports The Pharma Letter’s local correspondent. 5 June 2026
One to Watch Companies
One to watch
A neurology-focused specialty pharmaceutical company headquartered in Frankfurt am Main, Germany. It is active internationally, commercializing products across a broad set of markets through a mix of affiliates and partners.
One to watch
A biotech company focused on the development of a p300/CBP inhibitor to treat specific cancer types.
One to watch
A clinical-stage biotechnology company developing novel T-cell engagers for autoimmune and inflammatory diseases, Candid Therapeutics launched in 2024 with $370 million in Series A financing and agreed to a $2.2 billion acquisition by UCB in May 2026.
One to watch
A privately-held French biotech advancing a clinical pipeline of gamma delta T-cell-focused antibodies for cancer and autoimmune diseases.
Boardroom
Biotechnology
New Jersey, USA-based biotech Reunion Neuroscience has appointed Dr Sahil Kirpekar as its new president, chief executive (CEO) and a member of the board of Ddirectors, effective immediately. 16 June 2026
Biotechnology
Sweden’s Hansa Biopharma announced today the appointment of Adam Cutler as chief financial officer (CFO) and a member of the executive committee, effective June 22, 2026. 15 June 2026
Pharmaceutical
Canada-based clinical-stage drug developer ZYUS Life Sciences Corporation yesterday announced a strategic realignment of its corporate structure and leadership to strengthen its focus on the Company's core clinical development priorities. 12 June 2026
Biotechnology
Spanish women’s health biotech company Oriva Therapeutics has appointed Agnès Arbat as chief executive, as it advances a pipeline of treatments for chronic gynecological diseases led by the Phase I endometriosis candidate ORV-362. 11 June 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze